Allogeneic Anti-CD19 CAR-T cell therapy (Shanghai Zhongshan Hospital)

N/A

Report date: 2025/08/20 20:01:27

Base Information

Drug NameAllogeneic Anti-CD19 CAR-T cell therapy (Shanghai Zhongshan Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsGraves Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Zhongshan Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhongshan Hospital
Inactive CompaniesN/A
Active IndicationsGraves Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A